EUCODIS Bioscience Launches LacBuster(TM), a High-Performance Enzyme Inactivating a Broad Spectrum of Beta-Lactam Antibiotics

June 23, 2010

VIENNA, Austria, June 23, 2010 /PRNewswire/ — EUCODIS Bioscience, a
developer and manufacturer of customized enzymes today announced that it has
launched a high-performance beta-lactamase designed to inactivate a broad
range of beta-lactam antibiotics. EUCODIS Bioscience is marketing the product
under the LacBuster(TM) brand.

Beta-lactamases are enzymes that inactivate beta-lactam antibiotics,
hydrolyzing the beta-lactam ring, a molecular structure common to these
drugs. This property makes beta lactamases an important tool in the
manufacture of beta-lactam antibiotics, where they are used for sterility
testing of bulk products. Within the USD 25 billion antibiotics market,
beta-lactam antibiotics are the most widely prescribed group of drugs.
Beta-lactamase enzymes are also used by the diagnostics industry, and in
other areas.

“Our LacBuster(TM) beta-lactamase addresses the needs of leading
antibiotics manufacturers, as it inactivates all relevant beta-lactam
antibiotics, including penicillins, cephalosporins up to the 5th generation,
and carbapenems, and shows an activity significantly higher than that of
other products currently in the market”, said Bhupinder Hundle, Senior Vice
President Marketing & Sales, EUCODIS Bioscience.

“The launch of a product that provides a better performance than
previously available in the market demonstrates that we are deeply committed
to helping pharmaceutical manufacturers and drug developers keeping their
competitive edge”, said Thomas Fischer, CEO EUCODIS Bioscience. “At the same
time, demand from the broader chemical industry is gaining momentum. With our
enzyme products as well as our custom-engineering and manufacturing services
we have been making strong inroads in areas such as specialty chemicals,
cosmetics, animal feeds, as well as high-value products from biomass.”

About EUCODIS Bioscience

EUCODIS Bioscience provides enzymes to the chemical, health care, and
other industries, and offers custom-engineering and custom-manufacturing

Customers use EUCODIS Bioscience’ enzymes and services to make their
manufacturing processes more efficient and cleaner and to introduce products
with superior properties. The Company’s technology of in vivo-recombination
is a proven tool for the directed evolution of enzymes that perform to
customers’ specific requirements.

Enzymes are proteins that catalyze highly specific chemical reactions,
offering a safer, cleaner, and competitive alternative to traditional
chemistry. They are at the center of industrial, or “white” biotechnology, a
fast growing industry segment with sales in excess of EUR100 billion.

Led by an experienced management team, EUCODIS Bioscience is backed by
Austrian and German institutional venture capital funds, founders, and
private investors. The Company is headquartered in Austria, Europe, with a
subsidiary in Germany.

    For more information, please visit http://www.eucodisbioscience.com

    Company contact EUCODIS Bioscience:

    Thomas Fischer
    EUCODIS Bioscience
    Campus Vienna Biocenter II
    Viehmarktgasse 2 a/ 2 OG
    A-1030 Vienna

    Media contact EUCODIS Bioscience:
    Frank Butschbacher
    Investor Relations & Communications




Source: newswire

comments powered by Disqus